04-13 Aptamer Sciences Inc announced that it has received KRW 30.00043989 billion in funding from Alticast Corporation, Daihyun Eng & Const Co., Ltd., K&P Investment Co., Ltd., Vision 2 Co., Ltd., JDK Partners Co., Ltd. and other investors. CI
04-08 Aptamer Sciences Inc announced that it has received KRW 12 billion in funding CI
03-24 Aptamer Sciences Inc agreed to acquire Choolip Inc. from Wellnew & Co for $11.4 million. CI
02-12 Aptamer Sciences Inc announced that it has received KRW 7 billion in funding CI
02-09 FOCUS AI Co., Ltd. announced that it has received KRW 5.423916904 billion in funding from Aptamer Sciences Inc, Nex Plan Co., Ltd., 3S E&D Co., Ltd. CI
01-27 Aptamer Sciences Inc announced that it expects to receive KRW 12 billion in funding CI
01-25 FOCUS AI Co., Ltd. announced that it has received KRW 999.999944 million in funding from Aptamer Sciences Inc CI
01-15 Aptamer Sciences Inc announced that it expects to receive KRW 7 billion in funding from Bellum Fund 1 CI
12-18 FOCUS AI Co., Ltd. announced that it expects to receive KRW 999.999944 million in funding from Aptamer Sciences Inc CI
12-02 FOCUS AI Co., Ltd. announced that it expects to receive KRW 9.42391668 billion in funding from Aptamer Sciences Inc and other investors CI
25-10-23 Alticast Corporation completed the acquisition of 8.07% stake in Aptamer Sciences Inc from Han Dong-il, Ryu Seong-ho, Jang Seung-gi. CI
25-09-07 Alticast Corporation agreed to acquire an 8.07% stake in Aptamer Sciences Inc from Han Dong-il, Ryu Seong-ho, Jang Seung-gi for KRW 4.4 billion. CI
25-08-20 Aptamer Sciences wins 320 million won order RE
1 day-2.33%
1 week-11.79%
Current month-11.79%
1 month-15.69%
3 months-35.09%
6 months-23.82%
Current year+10.55%
1 week 1,625
Extreme 1625
2,130
1 month 1,625
Extreme 1625
2,130
Current year 1,350
Extreme 1350
3,996
1 year 1,350
Extreme 1350
3,996
3 years 1,350
Extreme 1350
9,750
5 years 1,350
Extreme 1350
27,750
10 years 1,350
Extreme 1350
38,350
Manager TitleAgeSince
Chief Executive Officer 54 2025-10-26
Director of Finance/CFO 56 2025-10-26
Chief Tech/Sci/R&D Officer 53 -
Director TitleAgeSince
Director/Board Member 54 2025-10-26
Director/Board Member 56 2025-10-26
Director/Board Member 51 2025-10-26
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-11.79%-27.57%-79.41% 36.19M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average -0.83%+0.28%+66.28%+89.37% 26.32B
Weighted average by Cap. -0.91%+0.59%+95.81%+132.92%
Logo CHOOLIP & SCIENCES Inc.
CHOOLIP & SCIENCES Inc, formerly Aptamer Sciences Inc., is a Korea-based company engaged in the research and development of bio therapeutic drugs business. The Company mainly engaged in the provision of contract research organization (CRO) services for conducting biopharmaceutical analysis. In addition, the Company is engaged in the provision of oligonucleotide synthesis and aptamer discovery services, developing biopharmaceuticals such as insulin receptors, and conducting distribution and sales of consumer goods and health-related consumer products.
Employees
-
Date Price Change Volume
26-08-14 ₩1,676.00 -2.33% 30,462
26-08-13 ₩1,716.00 -1.89% 24,982
  1. Stock Market
  2. Stocks
  3. A291650 Stock